MedTrace Logo

Serologic Surveillance for SARS-CoV-2 (COVID-19) in a Prospective Cohort of Health Care Workers

NCT04387890 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2020-05-28

No results posted yet for this study

Summary

The investigators will follow a single prospective cohort of 50 Health Care Workers in the Hospital Italiano de Buenos Aires (Argentina) from May 15th to August 31st 2020 using antibody testing for SARS-CoV-2 IgM and IgG at baseline and every 2 weeks in order to assess the incidence of COVID-19, the prevalence of anti-SARS-CoV-2 antibodies (IgM and IgG) and incidence of reinfection or reactivations of previous COVID-19 using viral gene sequencing in this cohort.

Conditions

Interventions

DIAGNOSTIC_TEST

Serologic SARS-CoV-2 screening

Quantitative Indirect Chemiluminescence Immunoassay (CLIA) to access SARS-CoV-2 specific IgM and IgG serum antibody level every 2 weeks during follow up

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Hospital Italiano de Buenos Aires

    lead OTHER

Principal Investigators

  • Leticia Peroni, MD · HIBA

  • Vanina Stanek, MD · HIBA

  • Diego Sanchez Thomas, MD · HIBA

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2020-08-31
Completion
2020-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04387890 on ClinicalTrials.gov